Large Molecule Drug Substance CDMO Market Size, Share, Trends, Growth Outlook

Large Molecule Drug Substance CDMO Market is estimated to increase at a growth rate of 9.4% CAGR over the forecast period from 2024 to 2030.

The global Large Molecule Drug Substance CDMO Marketstudy analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Service (Contract Manufacturing, Contract Development), By Source (Mammalian, Microbial, Others), By End-user (Biotech Companies, CRO, Others).

An introduction to Large Molecule Drug Substance CDMO Market in 2024

The Large Molecule Drug Substance Contract Development and Manufacturing Organization (CDMO) market in 2024 serves the growing demand for outsourced services in the development and manufacturing of large molecule therapeutics. Large molecule drugs, including monoclonal antibodies, recombinant proteins, and gene therapies, require specialized expertise and infrastructure for their production, purification, and formulation. Large molecule CDMOs offer a range of services, including cell line development, process optimization, scale-up, cGMP manufacturing, and analytical testing, to support biopharmaceutical companies throughout the drug development lifecycle. Market dynamics are influenced by factors such as the increasing pipeline of biologics, rising outsourcing trends, and the need for flexible and cost-effective manufacturing solutions. Collaboration between CDMOs, biopharmaceutical sponsors, regulatory authorities, and technology providers drives innovation in large molecule drug substance development and manufacturing, enabling accelerated timelines, reduced costs, and enhanced quality for biopharmaceutical products.

Large Molecule Drug Substance CDMO Market Trend: Increasing Outsourcing of Large Molecule Drug Substance Manufacturing

One prominent trend in the large molecule drug substance Contract Development and Manufacturing Organization (CDMO) market is the increasing outsourcing of large molecule drug substance manufacturing by pharmaceutical companies. As the demand for biologics and large molecule therapeutics continues to rise, pharmaceutical companies are turning to CDMOs for their expertise, specialized infrastructure, and flexible manufacturing capacities. Outsourcing allows pharmaceutical companies to leverage the capabilities of CDMOs, streamline their manufacturing processes, and focus on core competencies such as drug discovery and commercialization. This trend reflects a strategic shift towards a more collaborative and cost-effective approach to large molecule drug substance production, driving the growth of the CDMO market.

Large Molecule Drug Substance CDMO Market Driver: Growth of Biologics and Biosimilars Market

A significant driver fueling the growth of the large molecule drug substance CDMO market is the increasing demand for biologics and biosimilars worldwide. Biologics, including monoclonal antibodies, therapeutic proteins, and vaccines, represent a rapidly expanding segment of the pharmaceutical industry, offering novel treatment options for a wide range of diseases such as cancer, autoimmune disorders, and infectious diseases. As biologics gain prominence in the healthcare landscape, pharmaceutical companies are seeking reliable and cost-effective partners to support their biologics manufacturing needs. Additionally, the rise of biosimilars as more affordable alternatives to originator biologics further drives the demand for CDMOs capable of producing high-quality, cost-efficient drug substances to meet regulatory requirements and market demand.

Large Molecule Drug Substance CDMO Market Opportunity: Expansion into Cell and Gene Therapy Manufacturing

An emerging opportunity in the large molecule drug substance CDMO market lies in the expansion into cell and gene therapy manufacturing. With the rapid advancements in cell and gene therapy technologies and the approval of several cell-based and gene-based therapies, there is a growing demand for CDMOs with expertise in cell culture, viral vector production, and gene editing techniques. This presents an opportunity for existing CDMOs to diversify their service offerings and invest in specialized infrastructure and capabilities to support the development and manufacturing of cell and gene therapies. By expanding into this fast-growing segment of the biopharmaceutical industry, CDMOs can position themselves as strategic partners for biotech companies and pharmaceutical sponsors seeking end-to-end solutions for their cell and gene therapy programs.

Large Molecule Drug Substance CDMO Market Market Segmentation

By Service
Contract Manufacturing
-Clinical
-Commercial
Contract Development
-Cell Line Development
-Process Development
By Source
Mammalian
Microbial
Others
By End-User
Biotech Companies
CRO
Others

Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Large Molecule Drug Substance CDMO Market Companies

AGC Biologics
Boehringer Ingelheim
Catalent Inc
Eurofins Scientific
FUJIFILM Diosynth Biotechnologies
Recipharm AB
Rentschler Biopharma SE
Samsung Biologics
Siegfried Holding AG
WuXi Biologics

Reasons to Buy the Large Molecule Drug Substance CDMO Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Large Molecule Drug Substance CDMO Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Large Molecule Drug Substance CDMO Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Large Molecule Drug Substance CDMO Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Large Molecule Drug Substance CDMO Market Size Outlook, $ Million, 2021 to 2030
3.2 Large Molecule Drug Substance CDMO Market Outlook by Type, $ Million, 2021 to 2030
3.3 Large Molecule Drug Substance CDMO Market Outlook by Product, $ Million, 2021 to 2030
3.4 Large Molecule Drug Substance CDMO Market Outlook by Application, $ Million, 2021 to 2030
3.5 Large Molecule Drug Substance CDMO Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Large Molecule Drug Substance CDMO Industry
4.2 Key Market Trends in Large Molecule Drug Substance CDMO Industry
4.3 Potential Opportunities in Large Molecule Drug Substance CDMO Industry
4.4 Key Challenges in Large Molecule Drug Substance CDMO Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Large Molecule Drug Substance CDMO Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Large Molecule Drug Substance CDMO Market Outlook by Segments
7.1 Large Molecule Drug Substance CDMO Market Outlook by Segments, $ Million, 2021- 2030
By Service
Contract Manufacturing
-Clinical
-Commercial
Contract Development
-Cell Line Development
-Process Development
By Source
Mammalian
Microbial
Others
By End-User
Biotech Companies
CRO
Others

8 North America Large Molecule Drug Substance CDMO Market Analysis and Outlook To 2030
8.1 Introduction to North America Large Molecule Drug Substance CDMO Markets in 2024
8.2 North America Large Molecule Drug Substance CDMO Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Large Molecule Drug Substance CDMO Market size Outlook by Segments, 2021-2030
By Service
Contract Manufacturing
-Clinical
-Commercial
Contract Development
-Cell Line Development
-Process Development
By Source
Mammalian
Microbial
Others
By End-User
Biotech Companies
CRO
Others

9 Europe Large Molecule Drug Substance CDMO Market Analysis and Outlook To 2030
9.1 Introduction to Europe Large Molecule Drug Substance CDMO Markets in 2024
9.2 Europe Large Molecule Drug Substance CDMO Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Large Molecule Drug Substance CDMO Market Size Outlook by Segments, 2021-2030
By Service
Contract Manufacturing
-Clinical
-Commercial
Contract Development
-Cell Line Development
-Process Development
By Source
Mammalian
Microbial
Others
By End-User
Biotech Companies
CRO
Others

10 Asia Pacific Large Molecule Drug Substance CDMO Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Large Molecule Drug Substance CDMO Markets in 2024
10.2 Asia Pacific Large Molecule Drug Substance CDMO Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Large Molecule Drug Substance CDMO Market size Outlook by Segments, 2021-2030
By Service
Contract Manufacturing
-Clinical
-Commercial
Contract Development
-Cell Line Development
-Process Development
By Source
Mammalian
Microbial
Others
By End-User
Biotech Companies
CRO
Others

11 South America Large Molecule Drug Substance CDMO Market Analysis and Outlook To 2030
11.1 Introduction to South America Large Molecule Drug Substance CDMO Markets in 2024
11.2 South America Large Molecule Drug Substance CDMO Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Large Molecule Drug Substance CDMO Market size Outlook by Segments, 2021-2030
By Service
Contract Manufacturing
-Clinical
-Commercial
Contract Development
-Cell Line Development
-Process Development
By Source
Mammalian
Microbial
Others
By End-User
Biotech Companies
CRO
Others

12 Middle East and Africa Large Molecule Drug Substance CDMO Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Large Molecule Drug Substance CDMO Markets in 2024
12.2 Middle East and Africa Large Molecule Drug Substance CDMO Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Large Molecule Drug Substance CDMO Market size Outlook by Segments, 2021-2030
By Service
Contract Manufacturing
-Clinical
-Commercial
Contract Development
-Cell Line Development
-Process Development
By Source
Mammalian
Microbial
Others
By End-User
Biotech Companies
CRO
Others

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
AGC Biologics
Boehringer Ingelheim
Catalent Inc
Eurofins Scientific
FUJIFILM Diosynth Biotechnologies
Recipharm AB
Rentschler Biopharma SE
Samsung Biologics
Siegfried Holding AG
WuXi Biologics
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Service
Contract Manufacturing
-Clinical
-Commercial
Contract Development
-Cell Line Development
-Process Development
By Source
Mammalian
Microbial
Others
By End-User
Biotech Companies
CRO
Others